Abstract: The invention relates to a method for authenticating objects provided with a marker that contains nucleic acid.

Abstract: The invention relates to a platelike color effect pigment having the following structure: a) a metallic reflective core; b) a spacer layer made of a dielectric material, and; c) an, all in all, semitransparent absorber layer comprising, in essence, discrete metal particles that have an average diameter of 1 to 100 nm and optionally at least one other protective layer.

Abstract: Glass particles colored with at least one colorant, where the colored glass particles are glass platelets with an average diameter of 1 to 500 ?m and the colorants comprise or consist of at least one of metallic nanoparticles and metal oxides. The glass platelets are planar and the colorants are present in a concentration from 1% to 55% by weight, based on the total weight of the colored glass platelets. The disclosure further relates to a method for producing the colored glass particles and to the use thereof.

Abstract: This invention relates to new formulated lipid particles (FLiPs) comprising at least one of a single or double stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed or associated. These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung and muscle where they effect gene silencing.

Abstract: The invention relates to a platelike color effect pigment having the following structure: a) a metallic reflective core; b) a spacer layer made of a dielectric material, and; c) an, all in all, semitransparent absorber layer comprising, in essence, discrete metal particles that have an average diameter of 1 to 100 nm and optionally at least one other protective layer.

Abstract: The present invention relates to methods for inhibiting adieogenesis and methods for treating obesity, metabolic syndrome and non-insulin dependent diabetes mellitus by administering an agent that increases Foxa-2 or Fxr, or an agent that activates Fxr. The invention is further related to methods for identifying agents that increase Foxa-2 or Fxr, or activate Fxr, and the use of such agents for treatment of obesity, metabolic syndrome and non-insulin dependent diabetes mellitus. Methods of identifying agents that mediate the phosphorylation of the transcription factor Foxa-2 are provided. Such agents are useful in methods of treating Type 2 diabetes.

Abstract: The present invention relates to polyurethane cast elastomers which are prepared from higher molecular weight polyhydroxy compounds, durene diisocyanate and low molecular weight chain-lengthening and/or crosslinking agents. These elastomers are particularly useful for the production of moldings exposed to high mechanical stresses.

Abstract: The present invention relates to polyurethane cast elastomers which are prepared from higher molecular weight polyhydroxy compounds, durene diisocyanate and low molecular weight chain-lengthening and/or crosslinking agents. These elastomers are particularly useful for the production of moldings exposed to high mechanical stresses.

Abstract: A process is described for the production of a curable multi-component reaction mixture (and, in particular, a polyurethane), containing filler in which the reaction components are premixed and then mixed with the dry filler in a friction mixer having a conically shaped screw rotatable in a conical mixing chamber. The friction mixer is preferably operated under a fractional load at a low rotational speed.

Abstract: A process for the production of composite bodies consisting of a polyurethane core and a polyurethane covering, with the core being positioned inside a mold so that an average distance of at least 0.5 mm exists between the surface of the core and the internal wall of the mold. The gap between the core and the internal wall of the mold is filled with a reaction mixture composed of a) a polyisocyanate component, and b) a polyol component. The polyol component b) must have a weight ratio of carbon to oxygen of at least 2.5:1.